Member Info for BuenaVista

There are pros and cons of fishing in a small pool. You may not be getting the best, but you know what you're getting and you're not paying a recruitment consultancy $$$ and relying on their judgement of character when compatability within the team is such an important aspect of working together.

Https://patentscope.wipo.int/search/en/WO2025147677

Not FAP-cleavable. PSMA is prostate-specific membrane antigen.

Also, both CC and YB were at what gets described as Pfizer/Wyeth. Pfizer acquired Wyeth in 2009 so it's possible they have known each other since the time they worked at Wyeth. Or, asking around old business colleagues, YB's name came up for the CytoImmune job.

A fairly detailed bio here https://rocketreach.co/yulii-bogatyrenko-email_3250007 but Biopharma C&I, despite being the most recent appointment listed, is the only one without more details.

Anyway, you can see what his roles were at the previous organisations from this bio - but note you only get 5 free look-ups a month.

That was Grok, and not much help.

The consultancy referenced on the Stellular Bio website is Biopharma C&I, and there is no indication from the provided source that the full name is expanded beyond this. The abbreviation "C&I" likely stands for "Consulting and Innovation," but this is not explicitly confirmed in the source. The website describes Biopharma C&I as a biotechnology consulting firm working with private and public companies on business development, corporate strategy, commercialization, launch readiness, and R&D strategy, with Yulii Bogatyrenko listed as a Principal.Regarding its current status, the Stellular Bio website does not specify whether Biopharma C&I is still operational, but Bogatyrenko’s role as a Principal suggests activity at the time of the website's last update.

Additional sources mentioning Biopharma C&I in connection with Yulii Bogatyrenko include:

• A 2023 press release from Stellular Bio, which lists Bogatyrenko as CBO and a Principal at Biopharma C&I, indicating the consultancy was active at least through 2023.

• A 2025 industry report from BioSpace, which references Bogatyrenko’s involvement with Biopharma C&I in a discussion of biotech consulting trends, suggesting the firm remains relevant in the industry as of 2025.

No information from these sources or additional searches indicates that Biopharma C&I has ceased operations, so it is reasonable to conclude it still exists as of the latest available data in 2025. However, the lack of a dedicated website or detailed public records for Biopharma C&I limits definitive confirmation.If you need further details or want me to dig deeper into specific aspects (e.g., recent projects or additional mentions), please let me know!Citations:

-: BioSpace, "Biopharmaceuticals Market to Hit US$ 654.76 Billion by 2030," Coherent Market Insights, 2024-11-13.

-: Stellular Bio, "Leadership: Yulii Bogatyrenko," accessed 2025-07-15.

-: Stellular Bio Press Release, "Stellular Bio Announces Leadership Updates," 2023-09-20.

Can't help with the LinkedIn thing as I deleted my account some time ago and I have only the same superficial access as you do.

But what I did find out from a post by CC, as CEO of CytoImmune Therapeutics when she hired Yulii as CBO, was that she was using the hashtag #CellsCreateHope. She now uses the hashtag #PeptidesCreateHope and has branched out to #HopeWithoutCompromise. Imaginative, but I'm looking for something more than 'hope'.

https://www.linkedin.com/posts/graeme-bell-512964_cytoimmune-therapeutics-appoints-yulii-bogatyrenko-activity-7037415984420278272-hnGU

As regards his position as CBO at Stellular Bio, he is described as "Principal at Biopharma C&I, a biotechnology consulting firm that works with private and public companies in business development, corporate strategy, commercialization, launch readiness and R&D strategy." I'd guess C&I stands for Consultancy & Investment but I was unable to find anything about the business.

https://www.stellularbio.com/team/leadership/yulii-bogatyrenko

💦

There's no point answering the sealion's questions as they'll just be asked again tomorrow. Just as my question to the pub bore would always be 'Why?'

It looks like they're not rushing to do anything with CanSEEK as yet then - four years gone and nothing in the pipeline and likely no milestone payments, not that they'd be all that great if there were as the agreement for the first drug is a only for a total of $9.5m.

I didn't find any relevant patents in the US Patent Office or on Google either: https://tinyurl.com/47arn3vt

What's for lunch?

When does the football start?

Where's the cat?

Who parked their van blocking the drive?

These are the questions we really want answering you clown.

This appears to have disappeared down a hole. All I can find is the old POINT Biopharma pipeline page https://www.sec.gov/Archives/edgar/data/1811764/000181176421000017/pointbiopharmainvestorpr011.jpg showing that CanSEEK never made it out of the discovery stage.

Not long after POINT was acquired by Eli Lilly at the end of December 2023, CC confirmed - April? June? September? - that the partnership was still active. Did anyone enquire about the current status at this year's prelims?

As far as I can see, the whole of POINT seems to have disappeared. Does anyone know where POINT went within Lilly?

No clearly not that!

Were you using the less than sign?

The < may be taken for part of html code like > is. Maybe?

I do get the impression that the share price is being held at this level 31 / 32-33. Is this so some buyer can load up or get out (GSA?) at this price? Or is it just a balance of buyers and sellers? Who knows.

How will it break out? By news or continued lack of news I'd guess. So expect something, or nothing, by, or before, the Heights repayment due on the 21st.

Is this a dirt cheap buying opportunity or a fool's temptation? Time will tell.

Enjoy!

The current AVA6000 study Eligibility Criteria list these as contraindications under Exclusion Criteria:

10. Has a severe infection (requiring iv treatment) within 21 days prior to Cycle 1, Day 1 including, but not limited to, hospitalisation for complications of infection, bacteraemia, or severe pneumonia.

11. Has any other clinically significant active disease, metabolic dysfunction, physical examination finding, clinical laboratory finding, or reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug in the opinion of the investigator.

Major surgery within 21 days prior to Cycle 1, Day 1 (i.e. wound healing) used to be listed separately but now goes under the criterion 11 catch-all. Additionally, adequate liver and kidney function are covered in the Inclusion Criteria.

Earliest study record (20 July 2021): https://clinicaltrials.gov/study/NCT04969835?tab=history&a=1#eligibility-card

Currernt study record (10 April 2025): https://clinicaltrials.gov/study/NCT04969835?tab=history&a=9#eligibility-card

Thanks B2H. I'm sure Avacta will only be working on new pre|CISION substrates in the context of oncology - cytotoxics or whatever.

Licensing the platform out to other companies for use in oncology could get problematic if there is overlap with any of the >10 targets Avata is working on in-house but licensing out for other therapeutic areas could be very lucrative. For example, imagine anti-inflammatories or antibiotics being targetted to, and only to, sites of inflammation. How much would that be worth given the number of different classes of drugs in these disease areas (steroidal anti-inflammatories, NSAIs, and many different classes of antibiotics) and with the side-effects problems with the anti-inflammatories in particular, as well as GI reactions that some people have to antibiotics.

Predicting share prices and deserving of respect are two terms that are incompatible, as are Miles McNulty and integrity.

Yeah B2H, 3996 and all that!

Thanks Sandy, yes I think that was it, part of the 'other oncology targets (other than Topo I and Topo II)'. The use of the terms 'therapeutic classes' and 'targeted therapies' are confusing, perhaps deliberately ambiguous as they could mean other therapeutic methods of treating cancer or they could mean totally different diseases, or indeed cover both. Anyway, there is still that "cancer and other diseases" that takes the potential coverage outside of just cancer.